SCHEMBL18268691

SCHEMBL18268691

C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc(F)cc(OCc5cnc(C)nc5)c4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 18/20 0.62
▸ EGFR P00533 5/20 0.60
▸ BLK P51451 2/20 0.60
▸ TEC P42680 3/20 0.56
▸ BMX P51813 3/20 0.56
▸ TXK P42681 2/20 0.56
▸ LYN P07948 2/20 0.56
▸ FGFR2 P21802 2/20 0.56
▸ ITK Q08881 2/20 0.56
▸ FLT3 P36888 2/20 0.56
▸ RIPK2 O43353 1/20 0.56
▸ NR1I2 O75469 1/20 0.56
▸ SLC22A3 O75751 1/20 0.56
▸ LATS1 O95835 1/20 0.56
▸ NUDT14 O95848 1/20 0.56
▸ ABL1 P00519 1/20 0.56
▸ ERBB2 P04626 1/20 0.56
▸ LCK P06239 1/20 0.56
▸ FYN P06241 1/20 0.56
▸ PGR P06401 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18268847 0.96 BTK (0.56) BTKEGFRBLKFLT3KIT
SCHEMBL18268996 0.95 BTK (0.62) BTKEGFRBLKTECBMX
SCHEMBL18268844 0.91 EGFR (0.74) BTKEGFRBLKTECBMX
SCHEMBL18268692 0.90 BTK (0.69) BTKEGFRITKFLT3LCK
SCHEMBL18268843 0.89 BTK (0.70) BTKEGFRITKFLT3LCK
SCHEMBL18268990 0.89 BTK (0.58) BTKEGFRTECBMXTXK
SCHEMBL18269003 0.87 BTK (0.68) BTKEGFRBLKTECBMX
SCHEMBL18269016 0.87 BTK (0.73) BTKEGFRBLKTECBMX
SCHEMBL15613529 0.86 BTK (0.61) BTKEGFRLYNNUDT14ABL1
SCHEMBL18235680 0.86 EGFR (0.80) BTKEGFRBLKTECBMX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180179210-A1 Inhibitors of the TEC Kinase Enzyme Family PHARMASCIENCE INC. (CA) 2018-06-28 — — US disclosed
WO-2016187723-A1 INHIBITORS OF THE TEC KINASE ENZYME FAMILY PHARMASCIENCE INC. (CA) 2016-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179210-A1 Inhibitors of the TEC Kinase Enzyme Family TEC, BTK, LCK BTK 2/4885EGFR 671/4885BLK 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback